LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Health & Fitness
• Education
• Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 8,280,528 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

arthritis, rheumatoid, article, google, scholar, patients, treatment, cas, jak, efficacy, methotrexate, jakinibs, safety, inhibitor, rheumatol, tanaka, peficitinib, combination, study, information, tofacitinib, baricitinib, doubleblind, placebocontrolled, genovese, wang, phase, response, tübingen, privacy, cookies, content, data, review, inhibitors, diseasemodifying, antirheumatic, clinical, results, access, protein, van, randomised, dis, takeuchi, inadequate, publish, search, systematic, bettanin,

Topics {✒️}

jak/stat signal pathway interferon-β ifn-γ janus kinase/signal transducers anti-citrullinated protein antibodies márcia inês goettert anti-carbamylated protein antibodies interferon-α ifn-β month download article/chapter alessandro menna alves biotechnology graduate program randomized placebo-controlled study meta-analysis article 14 article inflammopharmacology aims beatriz fabris bettanin low disease activity matthias gehringer academic drug discovery phase iib study small molecule therapeutics phase iii study de freitas mvc full article pdf privacy choices/manage cookies van der heijde active rheumatoid arthritis placebo-controlled trial selective jak-1 inhibitor interleukin-6 ifn-α abbreviations anti-ccp dose-ranging study phase iii randomised genovese mc van vollenhoven rf rheumatoid arthritis equivalent code availability severe rheumatoid arthritis severe rheumatoid arthritis european economic area adjusted indirect comparison related subjects gutierrez-ureña sr connective tissue diseases ms kristine schmidt article rocha university center univates conditions privacy policy bone marrow oedema accepting optional cookies fernanda majolo ethics declarations conflict

Questions {❓}

• Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Current jakinibs for the treatment of rheumatoid arthritis: a systematic review
         description:One-third of patients with severe rheumatoid arthritis (RA) do not achieve remission or low disease activity, or they have side effects from cDMARD and bDMARD. They will need a new treatment option such as the small molecule JAK inhibitors. In this systematic review, we evaluate the efficacy and safety data of the current jakinibs: tofacitinib, peficitinib, decernotinib, upadacitinib, baricitinib and filgotinib in patients in whom treatment with conventional or biological disease-modifying antirheumatic drugs (cDMARD and/or bDMARD) failed. We searched for randomized controlled trials comparing efficacy and safety of jakinibs for RA treatment using the Web of Science, Scopus, PubMed, and clinicaltrials.gov databases with the terms: “rheumatoid arthritis” OR “arthritis rheumatoid” OR “RA” AND “inhibitor” OR “jak inhibitor” AND “clinical trial” OR “treatment” OR “therapy”. All jakinibs achieved good results in ACR 20, 50, 70 and with CRP-DAS28 for LDA and remission, upadacitinib showed better results compared to the others. In ESR-DAS28 for remission, tofacitinib achieved the best result. Regarding the safety of all jakinibs, peficitinib, baricitinib and filgotinib did not register deaths in their studies unlike tofacitinib that presented 11 deaths. Despite all benefits of jakinibs, the use in patients with severe liver and kidney disease should be avoided. Jakinibs in monotherapy or in combination with methotrexate can be considered a viable alternative in the treatment of moderate-to-severe RA. Even after failures with combination of cDMARDS and bDMARDS, jakinibs demonstrated efficacy.
         datePublished:2021-05-27T00:00:00Z
         dateModified:2021-05-27T00:00:00Z
         pageStart:595
         pageEnd:615
         sameAs:https://doi.org/10.1007/s10787-021-00822-x
         keywords:
            JAK inhibitors
            Small molecules
            Rheumatoid arthritis
            Pharmacology/Toxicology
            Immunology
            Rheumatology
            Gastroenterology
            Dermatology
            Allergology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-021-00822-x/MediaObjects/10787_2021_822_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-021-00822-x/MediaObjects/10787_2021_822_Fig2_HTML.png
         isPartOf:
            name:Inflammopharmacology
            issn:
               1568-5608
               0925-4692
            volumeNumber:29
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Cláudia Monfroni Rocha
               affiliation:
                     name:Universidade do Vale do Taquari, Univates
                     address:
                        name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alessandro Menna Alves
               affiliation:
                     name:University Center Univates
                     address:
                        name:School of Dentistry, University Center Univates, Lajeado, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Beatriz Fabris Bettanin
               affiliation:
                     name:Universidade do Vale do Taquari, Univates
                     address:
                        name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                        type:PostalAddress
                     type:Organization
                     name:University Center Univates
                     address:
                        name:School of Dentistry, University Center Univates, Lajeado, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fernanda Majolo
               affiliation:
                     name:Universidade do Vale do Taquari, Univates
                     address:
                        name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Matthias Gehringer
               affiliation:
                     name:Eberhard Karls Universität Tübingen
                     address:
                        name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
                     name:Tübingen Center for Academic Drug Discovery (TüCAD2)
                     address:
                        name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stefan Laufer
               affiliation:
                     name:Eberhard Karls Universität Tübingen
                     address:
                        name:Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
                     name:Eberhard Karls Universität Tübingen
                     address:
                        name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
                     name:Tübingen Center for Academic Drug Discovery (TüCAD2)
                     address:
                        name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Márcia Inês Goettert
               url:http://orcid.org/0000-0002-3648-5033
               affiliation:
                     name:Universidade do Vale do Taquari, Univates
                     address:
                        name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                        type:PostalAddress
                     type:Organization
                     name:Universidade do Vale do Taquari, Univates
                     address:
                        name:Medical Sciences Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Current jakinibs for the treatment of rheumatoid arthritis: a systematic review
      description:One-third of patients with severe rheumatoid arthritis (RA) do not achieve remission or low disease activity, or they have side effects from cDMARD and bDMARD. They will need a new treatment option such as the small molecule JAK inhibitors. In this systematic review, we evaluate the efficacy and safety data of the current jakinibs: tofacitinib, peficitinib, decernotinib, upadacitinib, baricitinib and filgotinib in patients in whom treatment with conventional or biological disease-modifying antirheumatic drugs (cDMARD and/or bDMARD) failed. We searched for randomized controlled trials comparing efficacy and safety of jakinibs for RA treatment using the Web of Science, Scopus, PubMed, and clinicaltrials.gov databases with the terms: “rheumatoid arthritis” OR “arthritis rheumatoid” OR “RA” AND “inhibitor” OR “jak inhibitor” AND “clinical trial” OR “treatment” OR “therapy”. All jakinibs achieved good results in ACR 20, 50, 70 and with CRP-DAS28 for LDA and remission, upadacitinib showed better results compared to the others. In ESR-DAS28 for remission, tofacitinib achieved the best result. Regarding the safety of all jakinibs, peficitinib, baricitinib and filgotinib did not register deaths in their studies unlike tofacitinib that presented 11 deaths. Despite all benefits of jakinibs, the use in patients with severe liver and kidney disease should be avoided. Jakinibs in monotherapy or in combination with methotrexate can be considered a viable alternative in the treatment of moderate-to-severe RA. Even after failures with combination of cDMARDS and bDMARDS, jakinibs demonstrated efficacy.
      datePublished:2021-05-27T00:00:00Z
      dateModified:2021-05-27T00:00:00Z
      pageStart:595
      pageEnd:615
      sameAs:https://doi.org/10.1007/s10787-021-00822-x
      keywords:
         JAK inhibitors
         Small molecules
         Rheumatoid arthritis
         Pharmacology/Toxicology
         Immunology
         Rheumatology
         Gastroenterology
         Dermatology
         Allergology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-021-00822-x/MediaObjects/10787_2021_822_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-021-00822-x/MediaObjects/10787_2021_822_Fig2_HTML.png
      isPartOf:
         name:Inflammopharmacology
         issn:
            1568-5608
            0925-4692
         volumeNumber:29
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Cláudia Monfroni Rocha
            affiliation:
                  name:Universidade do Vale do Taquari, Univates
                  address:
                     name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alessandro Menna Alves
            affiliation:
                  name:University Center Univates
                  address:
                     name:School of Dentistry, University Center Univates, Lajeado, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Beatriz Fabris Bettanin
            affiliation:
                  name:Universidade do Vale do Taquari, Univates
                  address:
                     name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                     type:PostalAddress
                  type:Organization
                  name:University Center Univates
                  address:
                     name:School of Dentistry, University Center Univates, Lajeado, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fernanda Majolo
            affiliation:
                  name:Universidade do Vale do Taquari, Univates
                  address:
                     name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Matthias Gehringer
            affiliation:
                  name:Eberhard Karls Universität Tübingen
                  address:
                     name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
                  name:Tübingen Center for Academic Drug Discovery (TüCAD2)
                  address:
                     name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stefan Laufer
            affiliation:
                  name:Eberhard Karls Universität Tübingen
                  address:
                     name:Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
                  name:Eberhard Karls Universität Tübingen
                  address:
                     name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
                  name:Tübingen Center for Academic Drug Discovery (TüCAD2)
                  address:
                     name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Márcia Inês Goettert
            url:http://orcid.org/0000-0002-3648-5033
            affiliation:
                  name:Universidade do Vale do Taquari, Univates
                  address:
                     name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                     type:PostalAddress
                  type:Organization
                  name:Universidade do Vale do Taquari, Univates
                  address:
                     name:Medical Sciences Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Inflammopharmacology
      issn:
         1568-5608
         0925-4692
      volumeNumber:29
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Universidade do Vale do Taquari, Univates
      address:
         name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
         type:PostalAddress
      name:University Center Univates
      address:
         name:School of Dentistry, University Center Univates, Lajeado, Brazil
         type:PostalAddress
      name:Universidade do Vale do Taquari, Univates
      address:
         name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
         type:PostalAddress
      name:University Center Univates
      address:
         name:School of Dentistry, University Center Univates, Lajeado, Brazil
         type:PostalAddress
      name:Universidade do Vale do Taquari, Univates
      address:
         name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
         type:PostalAddress
      name:Eberhard Karls Universität Tübingen
      address:
         name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
         type:PostalAddress
      name:Tübingen Center for Academic Drug Discovery (TüCAD2)
      address:
         name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
         type:PostalAddress
      name:Eberhard Karls Universität Tübingen
      address:
         name:Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany
         type:PostalAddress
      name:Eberhard Karls Universität Tübingen
      address:
         name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
         type:PostalAddress
      name:Tübingen Center for Academic Drug Discovery (TüCAD2)
      address:
         name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
         type:PostalAddress
      name:Universidade do Vale do Taquari, Univates
      address:
         name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
         type:PostalAddress
      name:Universidade do Vale do Taquari, Univates
      address:
         name:Medical Sciences Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Cláudia Monfroni Rocha
      affiliation:
            name:Universidade do Vale do Taquari, Univates
            address:
               name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
               type:PostalAddress
            type:Organization
      name:Alessandro Menna Alves
      affiliation:
            name:University Center Univates
            address:
               name:School of Dentistry, University Center Univates, Lajeado, Brazil
               type:PostalAddress
            type:Organization
      name:Beatriz Fabris Bettanin
      affiliation:
            name:Universidade do Vale do Taquari, Univates
            address:
               name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
               type:PostalAddress
            type:Organization
            name:University Center Univates
            address:
               name:School of Dentistry, University Center Univates, Lajeado, Brazil
               type:PostalAddress
            type:Organization
      name:Fernanda Majolo
      affiliation:
            name:Universidade do Vale do Taquari, Univates
            address:
               name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
               type:PostalAddress
            type:Organization
      name:Matthias Gehringer
      affiliation:
            name:Eberhard Karls Universität Tübingen
            address:
               name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
               type:PostalAddress
            type:Organization
            name:Tübingen Center for Academic Drug Discovery (TüCAD2)
            address:
               name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Stefan Laufer
      affiliation:
            name:Eberhard Karls Universität Tübingen
            address:
               name:Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany
               type:PostalAddress
            type:Organization
            name:Eberhard Karls Universität Tübingen
            address:
               name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
               type:PostalAddress
            type:Organization
            name:Tübingen Center for Academic Drug Discovery (TüCAD2)
            address:
               name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Márcia Inês Goettert
      url:http://orcid.org/0000-0002-3648-5033
      affiliation:
            name:Universidade do Vale do Taquari, Univates
            address:
               name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
               type:PostalAddress
            type:Organization
            name:Universidade do Vale do Taquari, Univates
            address:
               name:Medical Sciences Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
      name:School of Dentistry, University Center Univates, Lajeado, Brazil
      name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
      name:School of Dentistry, University Center Univates, Lajeado, Brazil
      name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
      name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
      name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
      name:Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany
      name:Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls Universität Tübingen, Tübingen, Germany
      name:Tübingen Center for Academic Drug Discovery (TüCAD2), Tübingen, Germany
      name:Cell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
      name:Medical Sciences Graduate Program, Universidade do Vale do Taquari, Univates, Lajeado, Brazil
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(81)

• How much income does https://www.springernature.com/gp/authors have?
• Check the income stats for https://link.springernature.com/home/
• https://order.springer.com/public/cart income
• How much profit is https://www.editorialmanager.com/iphm making per month?
• What's the financial intake of https://orcid.org/0000-0002-3648-5033?
• Earnings of https://www.springernature.com/gp/librarians/licensing/agc/journals
• How much money does https://doi.org/10.1136%2Fannrheumdis-2015-208267 generate?
• What's the income of http://scholar.google.com/scholar_lookup?&title=Comparing%20the%20effects%20of%20tofacitinib%2C%20methotrexate%20and%20the%20combination%2C%20on%20bone%20marrow%20oedema%2C%20synovitis%20and%20bone%20erosion%20in%20methotrexate-naive%2C%20early%20active%20rheumatoid%20arthritis%3A%20results%20of%20an%20exploratory%20randomised%20MRI%20study%20incorporating%20semiquantitative%20and%20quantitative%20techniques&journal=Ann%20Rheum%20Dis&doi=10.1136%2Fannrheumdis-2015-208267&volume=75&pages=1024-1033&publication_year=2016&author=Conaghan%2CPG&author=%C3%98stergaard%2CM&author=Bowes%2CMA&author=Wu%2CC&author=Fuerst%2CT&author=Heijde%2CD&author=Irazoque-Palazuelos%2CF&author=Soto-Raices%2CO&author=Hrycaj%2CP&author=Xie%2CZ&author=Zhang%2CR&author=Wyman%2CBT&author=Bradley%2CJD&author=Soma%2CK&author=Wilkinson%2CB?
• What's https://doi.org/10.1590%2FS0482-50042011000300002's gross income?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Consenso%20Da%20Sociedade%20Brasileira%20de%20Reumatologia%202011%20Para%20o%20Diagn%C3%B3stico%20e%20Avalia%C3%A7%C3%A3o%20Inicial%20Da%20Artrite%20Reumatoide&journal=Rev%20Bras%20Reumatol&doi=10.1590%2FS0482-50042011000300002&volume=51&pages=207-219&publication_year=2011&author=Mota%2CLMH&author=Cruz%2CBA&author=Brenol%2CCV&author=Pereira%2CIA&author=Fronza%2CLSR&author=Bertolo%2CMB&author=Freitas%2CMVC&author=Silva%2CNA&author=Louzada-Junior%2CP&author=Giorgi%2CRDN&author=Lima%2CRAC&author=Pinheiro%2CGRC make?
• How much does https://doi.org/10.1002%2Fart.39953 pull in monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Baricitinib%2C%20methotrexate%2C%20or%20combination%20in%20patients%20with%20rheumatoid%20arthritis%20and%20no%20or%20limited%20prior%20disease-modifying%20antirheumatic%20drug%20treatment&journal=Arthritis%20and%20Rheumatol&doi=10.1002%2Fart.39953&volume=69&pages=506-517&publication_year=2017&author=Fleischmann%2CR&author=Schiff%2CM&author=Heijde%2CD&author=Ramos-Remus%2CC&author=Spindler%2CA&author=Stanislav%2CM&author=Zerbini%2CCA&author=Gurbuz%2CS&author=Dickson%2CC&author=Bono%2CS&author=Schlichting%2CD&author=Beattie%2CS&author=Kuo%2CWL&author=Rooney%2CT&author=Macias%2CW&author=Takeuchi%2CT bring in each month?
• Get to know https://doi.org/10.1002%2Fart.38949's earnings
• http://scholar.google.com/scholar_lookup?&title=A%20randomized%2C%20double-blind%2C%20placebo-controlled%2C%20twelve-week%2C%20dose-ranging%20study%20of%20decernotinib%2C%20an%20oral%20selective%20JAK-3%20inhibitor%2C%20as%20monotherapy%20in%20patients%20with%20active%20rheumatoid%20arthritis&journal=Arthritis%20Rheumatol&doi=10.1002%2Fart.38949&volume=67&pages=334-343&publication_year=2015&author=Fleischmann%2CRM&author=Damjanov%2CNS&author=Kivitz%2CAJ&author=Legedza%2CA&author=Hoock%2CT&author=Kinnman%2CN's total income per month
• What's the profit of https://doi.org/10.1002%2Fart.39808?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20ABT-494%2C%20a%20selective%20JAK-1%20inhibitor%2C%20in%20a%20phase%20IIb%20study%20in%20patients%20with%20rheumatoid%20arthritis%20and%20an%20inadequate%20response%20to%20methotrexate&journal=Arthritis%20Rheumatol&doi=10.1002%2Fart.39808&volume=68&pages=2857-2866&publication_year=2016&author=Genovese%2CMC&author=Smolen%2CJS&author=Weinblatt%2CME&author=Burmester%2CGR&author=Meerwein%2CS&author=Camp%2CHS&author=Wang%2CL&author=Othman%2CAA&author=Khan%2CN&author=Pangan%2CAL&author=Jungerwirth%2CS
• Get to know what's the income of https://doi.org/10.1002%2Fart.39473
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=VX-509%20%28Decernotinib%29%2C%20an%20oral%20selective%20JAK-3%20inhibitor%2C%20in%20combination%20with%20methotrexate%20in%20patients%20with%20rheumatoid%20arthritis&journal=Arthritis%20Rheumatol&doi=10.1002%2Fart.39473&volume=68&pages=46-55&publication_year=2016&author=Genovese%2CMC&author=Vollenhoven%2CRF&author=Pacheco-Tena%2CC&author=Zhang%2CY&author=Kinnman%2CN each month?
• What's the monthly income of https://doi.org/10.1002%2Fart.40054?
• http://scholar.google.com/scholar_lookup?&title=Peficitinib%2C%20a%20JAK%20inhibitor%2C%20in%20combination%20with%20limited%20conventional%20synthetic%20disease-modifying%20antirheumatic%20drugs%20in%20the%20treatment%20of%20moderate-to-severe%20rheumatoid%20arthritis&journal=Arthritis%20Rheumatol&doi=10.1002%2Fart.40054&volume=69&pages=932-942&publication_year=2017&author=Genovese%2CMC&author=Greenwald%2CM&author=Codding%2CC&author=Zubrzycka-Sienkiewicz%2CA&author=Kivitz%2CAJ&author=Wang%2CA&author=Shay%2CK&author=Wang%2CX&author=Garg%2CJP&author=Cardiel%2CMH's financial summary
• How much money does https://doi.org/10.1001%2Fjama.2019.9055 make?
• http://scholar.google.com/scholar_lookup?&title=Effect%20of%20filgotinib%20vs%20placebo%20on%20clinical%20response%20in%20patients%20with%20moderate%20to%20severe%20rheumatoid%20arthritis%20refractory%20to%20disease-modifying%20antirheumatic%20drug%20therapy%3A%20the%20FINCH%202%20randomized%20clinical%20trial&journal=JAMA&doi=10.1001%2Fjama.2019.9055&volume=322&pages=315-325&publication_year=2019&author=Genovese%2CMC&author=Kalunian%2CK&author=Gottenberg%2CJE&author=Mozaffarian%2CN&author=Bartok%2CB&author=Matzkies%2CF&author=Gao%2CJ&author=Guo%2CY&author=Tasset%2CC&author=Sundy%2CJS&author=Vlam%2CK&author=Walker%2CD&author=Takeuchi%2CT's revenue stream
• What's the financial outcome of https://doi.org/10.1093%2Frheumatology%2Fkes367?
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=Novel%20small%20molecule%20therapeutics%20in%20rheumatoid%20arthritis&journal=Rheumatology%20%28oxford%29&doi=10.1093%2Frheumatology%2Fkes367&volume=52&pages=1155-1162&publication_year=2013&author=Kelly%2CV&author=Genovese%2CM?
• What's the financial intake of https://doi.org/10.1002%2Fart.39955?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Peficitinib%2C%20a%20JAK%20inhibitor%2C%20in%20the%20treatment%20of%20moderate-to-severe%20rheumatoid%20arthritis%20in%20patients%20with%20an%20inadequate%20response%20to%20methotrexate&journal=Arthritis%20Rheumatol&doi=10.1002%2Fart.39955&volume=69&pages=709-719&publication_year=2017&author=Kivitz%2CAJ&author=Gutierrez-Ure%C3%B1a%2CSR&author=Poiley%2CJ&author=Genovese%2CMC&author=Kristy%2CR&author=Shay%2CK&author=Wang%2CX&author=Garg%2CJP&author=Zubrzycka-Sienkiewicz%2CA?
• How much profit does https://doi.org/10.1177%2F1759720X18776224 generate?
• Profit of http://scholar.google.com/scholar_lookup?&title=The%20role%20of%20the%20JAK%2FSTAT%20signal%20pathway%20in%20rheumatoid%20arthritis&journal=Ther%20Adv%20Musculoskelet%20Dis&doi=10.1177%2F1759720X18776224&volume=10&pages=117-127&publication_year=2018&author=Malemud%2CCJ
• How much does http://scholar.google.com/scholar_lookup?&title=Discovery%20of%20a%20highly%20selective%20JAK3%20inhibitor%20for%20the%20treatment%20of%20rheumatoid%20arthritis&journal=Sci%20Rep&volume=8&publication_year=2018&author=Pei%2CH&author=He%2CL&author=Shao%2CM&author=Yang%2CZ&author=Ran%2CY&author=Li%2CD&author=Zhou%2CY&author=Tang%2CM&author=Wang%2CT&author=Gong%2CY&author=Chen%2CX&author=Yang%2CS&author=Xiang%2CM&author=Chen%2CL generate monthly?
• What's the revenue for https://doi.org/10.1016%2FS0140-6736%2819%2930419-2?
• http://scholar.google.com/scholar_lookup?&title=Upadacitinib%20as%20monotherapy%20in%20patients%20with%20active%20rheumatoid%20arthritis%20and%20inadequate%20response%20to%20methotrexate%20%28SELECT-MONOTHERAPY%29%3A%20a%20randomised%2C%20placebo-controlled%2C%20double-blind%20phase%203%20study&journal=Lancet&doi=10.1016%2FS0140-6736%2819%2930419-2&volume=393&pages=2303-2311&publication_year=2019&author=Smolen%2CJS&author=Pangan%2CAL&author=Emery%2CP&author=Rigby%2CW&author=Tanaka%2CY&author=Vargas%2CJI&author=Zhang%2CY&author=Damjanov%2CN&author=Friedman%2CA&author=Othman%2CAA&author=Camp%2CHS&author=Cohen%2CS's revenue stream
• What's the profit of https://doi.org/10.1136%2Fannrheumdis-2015-208279?
• http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20the%20oral%20janus%20kinase%20inhibitor%20peficitinib%20%28ASP015K%29%20monotherapy%20in%20patients%20with%20moderate%20to%20severe%20rheumatoid%20arthritis%20in%20Japan%3A%20a%2012-week%2C%20randomised%2C%20double-blind%2C%20placebo-controlled%20phase%20IIb%20study&journal=Ann%20Rheum%20Dis&doi=10.1136%2Fannrheumdis-2015-208279&volume=75&pages=1057-1064&publication_year=2016&author=Takeuchi%2CT&author=Tanaka%2CY&author=Iwasaki%2CM&author=Ishikura%2CH&author=Saeki%2CS&author=Kaneko%2CY income
• Discover the revenue of https://doi.org/10.1136%2Fannrheumdis-2019-215164
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20peficitinib%20%28ASP015K%29%20in%20patients%20with%20rheumatoid%20arthritis%20and%20an%20inadequate%20response%20to%20methotrexate%3A%20results%20of%20a%20phase%20III%20randomised%2C%20double-blind%2C%20placebo-controlled%20trial%20%28RAJ4%29%20in%20Japan&journal=Ann%20Rheum%20Dis&doi=10.1136%2Fannrheumdis-2019-215164&volume=78&pages=1305-1319&publication_year=2019&author=Takeuchi%2CT&author=Tanaka%2CY&author=Tanaka%2CS&author=Kawakami%2CA&author=Iwasaki%2CM&author=Katayama%2CK&author=Rokuda%2CM&author=Izutsu%2CH&author=Ushijima%2CS&author=Kaneko%2CY&author=Shiomi%2CT&author=Yamada%2CE&author=Heijde%2CD generate?
• How much does https://doi.org/10.3899%2Fjrheum.150613 pull in?
• What's http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20baricitinib%20in%20Japanese%20patients%20with%20active%20rheumatoid%20arthritis%20receiving%20background%20methotrexate%20therapy%3A%20a%2012-week%2C%20double-blind%2C%20randomized%20placebo-controlled%20study&journal=J%20Rheumatol&doi=10.3899%2Fjrheum.150613&volume=43&pages=504-511&publication_year=2016&author=Tanaka%2CY&author=Emoto%2CK&author=Cai%2CZ&author=Aoki%2CT&author=Schlichting%2CD&author=Rooney%2CT&author=Macias%2CW's gross income?
• See how much https://doi.org/10.1136%2Fannrheumdis-2019-215163 makes per month
• How much does http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20of%20peficitinib%20%28ASP015K%29%20in%20patients%20with%20rheumatoid%20arthritis%20and%20an%20inadequate%20response%20to%20conventional%20DMARDs%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%20Phase%20III%20trial%20%28RAJ3%29&journal=Ann%20Rheum%20Dis&doi=10.1136%2Fannrheumdis-2019-215163&volume=78&pages=1320-1332&publication_year=2019&author=Tanaka%2CY&author=Takeuchi%2CT&author=Tanaka%2CS&author=Kawakami%2CA&author=Iwasaki%2CM&author=Song%2CYW&author=Chen%2CYH&author=Wei%2CJC&author=Lee%2CSH&author=Rokuda%2CM&author=Izutsu%2CH&author=Ushijima%2CS&author=Kaneko%2CY&author=Akazawa%2CR&author=Shiomi%2CT&author=Yamada%2CE pull in?
• What's the income generated by https://doi.org/10.5114%2Freum.2020.102006 each month?
• How much does http://scholar.google.com/scholar_lookup?&title=Baricitinib%20for%20the%20treatment%20of%20rheumatoid%20arthritis&journal=Reumatologia%20Rheumatology&doi=10.5114%2Freum.2020.102006&volume=58&pages=407-415&publication_year=2020&author=Urits%2CI&author=Israel%2CJ&author=Hakobyan%2CH&author=Yusin%2CG&author=Lassiter%2CG&author=Fackler%2CN&author=Berger%2CA&author=Kassem%2CH&author=Kaye%2CA&author=Viswanath%2CO net monthly?
• https://doi.org/10.1002%2Fart.40803's financial summary
• How much does http://scholar.google.com/scholar_lookup?&title=Tofacitinib%20in%20combination%20with%20methotrexate%20in%20patients%20with%20rheumatoid%20arthritis%3A%20clinical%20efficacy%2C%20radiographic%2C%20and%20safety%20outcomes%20from%20a%20twenty-four%E2%80%93month%2C%20phase%20III%20study&journal=Arthritis%20Rheumatol&doi=10.1002%2Fart.40803&volume=71&pages=878-891&publication_year=2019&author=Heijde%2CD&author=Strand%2CV&author=Tanaka%2CY&author=Keystone%2CE&author=Kremer%2CJ&author=Zerbini%2CCAF&author=Cardiel%2CMH&author=Cohen%2CS&author=Nash%2CP&author=Song%2CYW&author=Tegzov%C3%A1%2CD&author=Gruben%2CD&author=Wallenstein%2CG&author=Connell%2CCA&author=Fleischmann%2CR earn?
• Get to know http://scholar.google.com/scholar_lookup?&title=From%20rheumatoid%20factor%20to%20anti-citrullinated%20protein%20antibodies%20and%20anti-carbamylated%20protein%20antibodies%20for%20diagnosis%20and%20prognosis%20prediction%20in%20patients%20with%20rheumatoid%20arthritis&journal=Int%20J%20Mol%20Sci&volume=22&pages=1-18&publication_year=2021&author=Yi%2CWC&author=Yang%2CHY&author=Luo%2CSF&author=Lai%2CJH's earnings
• How much revenue does http://scholar.google.com/scholar_lookup?&title=JAK%20inhibitors%3A%20prospects%20in%20connective%20tissue%20diseases&journal=Clin%20Rev%20Allergy%20Immunol&doi=10.1007%2Fs12016-020-08786-6&volume=5&pages=334-351&publication_year=2020&author=You%2CH&author=Xu%2CD&author=Zhao%2CJ&author=Li%2CJ&author=Wang%2CQ&author=Tian%2CX&author=Li%2CM&author=Zeng%2CX bring in?
• What's the total monthly financial gain of https://citation-needed.springer.com/v2/references/10.1007/s10787-021-00822-x?format=refman&flavour=references?
• What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cl%C3%A1udia%20Monfroni%20Rocha?
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cl%C3%A1udia%20Monfroni%20Rocha%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alessandro%20Menna%20Alves's revenue stream
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alessandro%20Menna%20Alves%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Beatriz%20Fabris%20Bettanin rake in every month?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Beatriz%20Fabris%20Bettanin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fernanda%20Majolo?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fernanda%20Majolo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Matthias%20Gehringer each month?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Matthias%20Gehringer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• What's https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stefan%20Laufer's gross income?
• What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stefan%20Laufer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%C3%A1rcia%20In%C3%AAs%20Goettert have monthly?
• How profitable is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%C3%A1rcia%20In%C3%AAs%20Goettert%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the profit of https://static-content.springer.com/esm/art%3A10.1007%2Fs10787-021-00822-x/MediaObjects/10787_2021_822_MOESM1_ESM.docx?
• What's the revenue for https://static-content.springer.com/esm/art%3A10.1007%2Fs10787-021-00822-x/MediaObjects/10787_2021_822_MOESM2_ESM.docx?
• What is the earnings of https://s100.copyright.com/AppDispatchServlet?title=Current%20jakinibs%20for%20the%20treatment%20of%20rheumatoid%20arthritis%3A%20a%20systematic%20review&author=Cl%C3%A1udia%20Monfroni%20Rocha%20et%20al&contentID=10.1007%2Fs10787-021-00822-x©right=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20Switzerland%20AG&publication=0925-4692&publicationDate=2021-05-27&publisherName=SpringerNature&orderBeanReset=true?
• What's the profit of https://crossmark.crossref.org/dialog/?doi=10.1007/s10787-021-00822-x?
• What's the financial outcome of https://citation-needed.springer.com/v2/references/10.1007/s10787-021-00822-x?format=refman&flavour=citation?
• Learn about the earnings of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral
• Learn about the earnings of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
• How much does https://www.springernature.com/gp/products generate monthly?
• What's the income of https://www.springernature.com/gp/librarians?
• How much profit is https://www.springernature.com/gp/societies making per month?
• Check the income stats for https://www.springernature.com/gp/partners
• What's the monthly income of https://www.springer.com/?
• How much does https://www.nature.com/ bring in each month?
• Check the income stats for https://www.biomedcentral.com/
• Profit of https://www.palgrave.com/
• Earnings of https://www.apress.com/
• How much profit does https://www.springernature.com/gp/legal/ccpa make?
• What's https://www.springernature.com/gp/info/accessibility's gross income?
• What are the earnings of https://support.springernature.com/en/support/home?
• Revenue of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
• What's the monthly income of https://www.springernature.com/?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref